Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533285 | 1.00 | SLC6A3 (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL1794707 | 1.00 | SLC6A3 (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL13403260 | 0.98 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20439223 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL6674308 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL5177411 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482420 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482130 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482096 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL9872556 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| EP-1527048-B1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1527048-A2 | N- PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013101-A2 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013100-A2 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | WO | disclosed |
| EP-0572449-A1 | (AMIDOMETHYL)NITROGEN HETEROCYCLIC ANALGESICS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-12-08 | — | — | EP | disclosed |
| US-5254569-A | Side effect reduction; diuretics; anticonvulsants | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1992012128-A1 | (AMIDOMETHYL)NITROGEN HETEROCYCLIC ANALGESICS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | HDAC6, NAT1, ARG2 | SLC6A3 1390/4885SLC6A2 1222/4885SLC6A4 1290/4885 |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | HDAC6, NAT1, ARG2 | SLC6A3 1390/4885SLC6A2 1222/4885SLC6A4 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.